Athena Countouriotis, President & CEO at Turning Point Therapeutics, Inc. (TPTX), sold 113,697 shares at $136.45 ($15.6M) on 2021-02-11, disclosed to the SEC on 2021-02-11.
Open-market sale of $15.6M TPTX by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $136.29 | 6,200 | $845K | 5.4% |
| 2 | $137.58 | 103 | $14K | 0.1% |
| 3 | $138.66 | 4,969 | $689K | 4.4% |
| 4 | $138.66 | 4,969 | $689K | 4.4% |
| 5 | $139.69 | 13,290 | $1.9M | 11.9% |
| 6 | $139.69 | 13,290 |
| $1.9M |
| 11.9% |
| 7 | $140.24 | 1,104 | $155K | 1.0% |
| 8 | $140.24 | 1,104 | $155K | 1.0% |
| 9 | $134.34 | 1,025 | $138K | 0.9% |
| 10 | $134.34 | 1,025 | $138K | 0.9% |
| 11 | $135.72 | 5,227 | $709K | 4.5% |
| 12 | $135.72 | 5,227 | $709K | 4.5% |
| 13 | $136.42 | 16,626 | $2.3M | 14.5% |
| 14 | $136.42 | 16,626 | $2.3M | 14.5% |
| 15 | $137.46 | 2,081 | $286K | 1.8% |
| 16 | $137.46 | 2,081 | $286K | 1.8% |
| 17 | $138.19 | 433 | $60K | 0.4% |
| 18 | $138.19 | 433 | $60K | 0.4% |
| 19 | $136.45 | 4,319 | $589K | 3.8% |
| 20 | $136.45 | 4,319 | $589K | 3.8% |
| 21 | $137.66 | 1,571 | $216K | 1.4% |
| 22 | $137.66 | 1,571 | $216K | 1.4% |
| 23 | $138.55 | 3,052 | $423K | 2.7% |
| 24 | $138.55 | 3,052 | $423K | 2.7% |
| Total | $137.55 avg | 113,697 | $15.6M | 100% |
| Filing → |
| PASG | BUY | 2020-03-25 | $150K | — | Filing → |
| PASG | BUY | 2020-03-03 | $160K | — | Filing → |
| TPTX | BUY | 2019-09-11 | $450K | — | Filing → |